1. C ompany Overview
Pres entation is prepared for S kolkovo Foundation
2012

2. Key Facts
 Company status Private Russian biotech company
 Founded 2011
Developing and marketing novel drugs for treatment of
cardiovascular diseases
 Our mission
Cardiovascular diseases
AHRO-001 – innovative drug for hyperlipidemia treatment and
 Main focus atherosclerotic prevention (co-development with AtheroNova, Inc.
(OTCBB: AHRO)
 Main product
Maxwell Biotech Venture Fund
- Maxwell Biotech Group - RVC
 Investors - AtheroNova, Inc - Skolkovo
 Partners
2

3. AHRO-001 Summary
 Product: bile salt administered via tablet;
 Mechanism of action: through the delipidization, the compound is designed to dissolve plaque
within the walls of the arteries and safely remove it from the body through natural metabolic
processes;
 Markets: global market is estimated at about $27 bln.; Russian market volume is $100 mln.
with a great potential for growth;
 Competitive advantages: the compound acquired all the advantages of the current
hyperlipidemia treatment molecules of different classes and also has a unique therapy effect –
atherosclerotic plaque regression;
 In vitro/In vivo: over 15 weeks of treatment showed significant VLDL/IDL/LDL cholesterol levels
decrease as well as significant suppression of plaque development (in aorta by 47%, in
innominate artery by 94%);
 Development status: toxicology/pharmacokinetics and formulation development studies
undergoing to initiate clinical trials.
3

4. Pathogenesis
Hypelipidemia and atherosclerosis:
 Lipid metabolism disoder;
 Increased in permeability of low density lipoprotein (LDL) through vessel
walls;
 Accumulation of cholesterol and LDL cholesterol;
 Formation of atherosclerotic plaques;
 Ischemic condition.
- Aorta atherosclerosis
- Myocardial infarction (coronary artery);
- Brain ischemia (innominate artery);
- Arteriosclerosis of the extremities etc.
4

5. Global Market
Worldwide anti-hyperlipidaemic drugs market is about $27 bln. (2010 )
“Gold standard” therapy – HMG-CoA reductase inhibitors – statins.
Additional therapy includes:
 Fibrates;
 Cholesterol absorption inhibitors;
 Nicotinic acid derivatives;
 Unsaturated fatty acids
Blockbuster drugs sales (2010):
 Atorvastatin (Lipitor, Pfizer) — $10.8 bln.;
 Rosuvastatin (Crestor, AstraZeneca) — $5.69 bln.;
 Simvastatin (Zocor, Merck, Bayer) — $4 bln.
“Gold standard” therapy cannot provide effective plaque regression without adverse effects
5

6. Russian Market
Russian market volume (2011) – ~ 3,5 bln. rubles (~ $100 mln.)
Statins
Simvastatin — 36%;
Cholesterol absorption
inhibitors Atorvastatin — 35%;
Fibrates
Rosuvastatin — 23%;
Nicotinic acid derivatives
Others — 6%
Unsaturated fatty acids
• Low disorders detection;
• Small share of the patients getting treatment;
• Patients are mainly using low-price generic drugs;
• Excessive price for non-statin agents.
6

7. AHRO-001
Bile salt (safe Regression of arterial
compound) plaques
- Increasing HDL levels; - Commercial manufacturing available;
- Decreasing LDL levels. - Low cost drug
7

8. Competitive Advantages
Drug CETP Ezetimibe
AHRO-001 Statins Niaspan
Effect Inhibitors (Zetia)
Emulsification of plaque  - - - -
Upregulation of  - - - -
ABCA1/ABCG1 gene
Decrease in cholesterol  - -  -
absorption
Potential plaque reversibility  * - - -
Decrease of plasma LDL     
cholesterol levels
Increase of HDL efficiency  -  - -
Stimulation of reverse  -   -
cholesterol transport
Atheroprotective effect   -  
*minimal efficacy at max dosage
8

9. AHRO-001 (Preclinical Trials)
In vitro results:
 lipidic core of the atherosclerotic plaque was almost entirely dissolved by AHRO-001;
 no damage to arterial wall;
 preserving the tensile strength of a normal arterial wall.
Aortas prepared en face
In vivo results:
 significant suppression of plaque development 1.25%
AHRO-001
over 15 weeks of treatment (in aorta by 47%, in
innominate artery by 94%);
 plasma VLDL/IDL/LDL cholesterol levels
Control group
decreased by 61% compare to control group;
 decrease in dietary cholesterol absorption by
76%; Plaque stained RED
9

10. Team
Chief Executive Officer
Andrey Boldyrev
- project management experience within Russian National Union of Business Angels;
- experience as an expert on intellectual property in the area of ​"biotechnology" in the FGU FIPS
(Federal service for intellectual property, patent and trademark);
- academic background with honors in biochemistry and professional experience in bioorganic
chemistry in Institute of Bioorganic Chemistry (Russian Academy of Science)
Chief Scientific Adviser
Ivan Gordeev, M.D.
- practicing cardiologist;
- professor of the Russian State Medical University (RSMU);
- broad experience working in clinical trials of multiple drug cantdidates for treatment of
acrdiovascular diseases.
Co-development partner: AtheroNova Inc. is involved in all the development steps of AHRO-001 including
manufacturing, formulation development, preclinical and clinical trials. For more information about
AtheroNova’s team experience you can visit their website at www.atheronova.com
The Company is actively using Maxwell Biotech competencies including scientific, clinical and development assistance.
18

11. Thank you for your attention
For more information, please contact:
Andrey Boldyrev, CEO
CardioNova, Ltd.
tel: +7 (495) 411-6992
office 3.29, Alexander House,
1 Bolshaya Yakimanka str.
Moscow, 119180, Russia
boldyrev@cardionova.ru